Aspira Women's Health finalizes CEO Buhle separation: $200K severance, 64,583 options accelerated

Aspira Women's Health Inc.

Cash severance $200,000 (6 months base salary) payable in installments; prorated $4,615.38 on July 15 payroll if signed by June 29.
Accelerated vesting of 64,583 stock options at $0.07/share, subject to Compensation Committee approval; all other unvested options forfeited.
Shares from accelerated options subject to restrictions: 90-day lock-up, daily volume limit 2,500 shares, price floor $0.45, approved broker, advance notice.
COBRA premium payments for 6 months; mutual release of claims; Buhle remains bound by confidentiality, non-solicitation, non-interference covenants.
Separation Agreement effective after 7-day revocation period (expected July 6, 2026).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Michael Buhle

Chief Executive Officer

AWHL · Aspira Women's Health Inc.

Effective: 2026-06-17
Successor: John (Jack) Fraser
Filed: July 7, 2026, 4:32 PM ET

Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026

Appointed (interim)

John (Jack) Fraser

Interim Chief Executive Officer

AWHL · Aspira Women's Health Inc.

Filed: July 7, 2026, 4:32 PM ET

appointed John (Jack) Fraser as Interim Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Buhle departed as Chief Executive Officer at Aspira Women's Health Inc..

Action: ceased serving
Role: Chief Executive Officer

Exact text from the filing

Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John (Jack) Fraser was appointed as Interim Chief Executive Officer at Aspira Women's Health Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

appointed John (Jack) Fraser as Interim Chief Executive Officer

View on SEC.gov

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-26-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.